SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer-Reference-Cited by-同舟云学术

SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer

Published:2016-07-11 Issue:47 Volume:7 Page:76628-76634
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Zhu Anjie¹,Yuan Peng¹,Du Feng¹,Hong Ruoxi²,Ding Xiaoyan³,Shi Xiuqing⁴,Fan Ying¹,Wang Jiayu¹,Luo Yang¹,Ma Fei¹,Zhang Pin¹,Li Qing¹,Xu Binghe¹

Affiliation:

1. Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College(CAMS&PUMC), Beijing, China

2. Department of Medical Oncology, Sun Yat-sen University Cancer center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China

3. Department of Medical Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing, China

4. Department of Medical Oncology, Yuhuangding Hospital, Yantai, Shandong, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients;Biomedicines;2023-12-06

2. Effect of variables on exemestane-loaded albumin nanoparticles: statistical optimization and anti-cancer activity in MCF-7 cell lines;Pharmaceutical Development and Technology;2023-11-26

3. Intracellular Fate of Sub-Toxic Concentration of Functionalized Selenium Nanoparticles in Aggressive Prostate Cancer Cells;Nanomaterials;2023-11-22

4. SPARC: a potential target for functional nanomaterials and drugs;Frontiers in Molecular Biosciences;2023-07-28

5. SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity;International Journal of Cancer;2022-11-30